Section

Pharma

Drug pipeline, pricing, industry

PBS NewsHour

FDA Approves New Drug for Advanced Pancreatic Cancer; Developments in Cancer Vaccines

The FDA has approved a new drug, daraxonrasib, for advanced pancreatic cancer, which has shown to nearly double patient survival times. Additionally, a new individualized mRNA vaccine for melanoma has demonstrated positive results in clinical trials, potentially lowering relapse rates. Experts express optimism about the future of cancer treatments and vaccines.

Bias: 4 Sentiment: +0.50
Daily Wire

FDA Approves New Treatment for Advanced Pancreatic Cancer

The FDA has approved daraxonrasib, branded as Rasonque, for the treatment of advanced pancreatic cancer. The approval follows a clinical trial showing that the drug nearly doubled median survival rates compared to standard chemotherapy. Experts highlight the significance of this treatment for patients with metastatic pancreatic adenocarcinoma.

Bias: 4 Sentiment: +0.50
The Atlantic

FDA Advisory Committee Recommends Compounding of BPC-157 Peptide

An FDA advisory committee has recommended that compounding pharmacies be allowed to produce BPC-157, a peptide with limited human safety data. The decision, which passed with an 8-6 vote, aims to provide safer access to the peptide amid concerns about unregulated online sales. Other peptides were also recommended, indicating potential growth in the market for these substances.

Bias: 4 Sentiment: +0.00